Inhibition of HER2 driver mutations can confer benefits
Amplification or overexpression of HER2 (ErbB2) has been identified in NSCLC, and somatic HER2 mutations occur in approximately 2 % to 4 % of patients. Response to chemotherapy is poor in the setting of HER2-mutant advanced NSCLC [3]. Similarly, single-agent pan-HER inhibitors appear to have only limited benefit, with rare and short-lived responses.